Ultragenyx (RARE) Shares Positive Results From DTX301 Phase 3 Study
Ultragenyx Pharmaceutical reported that its Phase 3 Enh3ance trial of DTX301, an AAV8 gene therapy for ornithine transcarbamylase deficiency, achieved an 18% reduction in 24‑hour plasma ammonia versus placebo at Week 36, with average ammonia levels staying within normal range. Eight of nine patients who entered the study with elevated ammonia quickly normalized and often maintained those levels. JPMorgan cut its price target for Ultragenyx from $120 to $74 but kept an Overweight rating, citing the need for further pipeline validation. The company continues to burn cash heavily while targeting profitability by 2027.
Soleno Therapeutics (SLNO) Still Appears Attractive Despite Slower U.S. Launch Ramp Projections
Oppenheimer kept an Outperform rating on Soleno Therapeutics but lowered its price target to $80 from $110, signaling a potential upside of more than 166%. Wells Fargo trimmed its target slightly to $110 while remaining Overweight. Both firms highlighted a slower‑than‑expected...
Mineralys Therapeutics (MLYS) Garnering Attention With Lorundrostat Progress
Mineralys Therapeutics (NASDAQ:MLYS) received a renewed Buy rating from Bank of America Securities, which lifted its price target to $51 from $46 after the company reported fourth‑quarter results. The firm highlighted progress on lorundrostat, an aldosterone synthase inhibitor, noting the...
ACC 2026: Sotatercept Shows Signal in CpcPH-HFpEF at Lower Dose
At the 2026 ACC Scientific Session, the phase‑II CADENCE trial showed that sotatercept (WINREVAIR) reduced pulmonary vascular resistance in adults with combined post‑ and precapillary pulmonary hypertension linked to HFpEF (CpcPH‑HFpEF). The study randomized 164 patients, median age 75, to...
Six Biotech Companies in Berlin to Watch in 2026
Berlin’s biotech sector is gaining global traction, highlighted by six innovative firms. 3B Pharmaceuticals secured a Novartis licensing deal for its FAP‑2286 radioligand and is collaborating on an astatine‑211 candidate. Ariceum Therapeutics dosed its first patient in a phase 1/2 trial...
Symeres and Ambagon Collaborate for Colorectal Cancer Molecules
Symeres has partnered with Ambagon Therapeutics to evaluate molecular‑glue compounds for colorectal cancer. The collaboration will leverage Symeres’ in‑vitro assays, surface‑plasmon resonance kinetics, and fluorescence microscopy to characterize ternary‑complex formation and downstream pathway effects. Symeres will also profile each candidate...
Symeres and Ambagon Collaborate for Colorectal Cancer Molecules
Symeres has partnered with Ambagon Therapeutics to evaluate Ambagon’s molecular glue candidates for colorectal cancer. The collaboration will use Symeres’ in‑vitro assays, surface plasmon resonance, fluorescence microscopy and a 102‑cell line panel to characterize ternary complex kinetics and downstream pathway...
STAT+: The Biotech Scorecard for the Second Quarter: 23 Stock-Moving Events to Watch
STAT’s quarterly biotech scorecard lists 23 upcoming events that could move biotech stocks in Q2 2026. Highlights include Phase 3 results from Abivax’s obefazimod in ulcerative colitis and Allogene Therapeutics’ interim data on its cema‑cel CAR‑T therapy for B‑cell lymphoma. The...
Lilly Moves Deeper Into Sleep Medicine with up to $7.8 Billion Centessa Deal
Eli Lilly announced a definitive agreement to acquire UK‑based Centessa Pharmaceuticals for up to $7.8 billion, paying $38 per share in cash and up to $9 per share in contingent milestones. The acquisition gives Lilly control of Centessa’s orexin‑receptor‑2 agonist pipeline,...
Anavex Updates Regulatory Strategy for Blarcamesine
Anavex Life Sciences has withdrawn its European Union marketing authorization application for blarcamesine and will collect additional data while maintaining dialogue with the European Medicines Agency. The company has concurrently submitted new data to the U.S. FDA to explore a...
Insilico Medicine, Lilly Partner on AI-Driven Drug Discovery Deal
Insilico Medicine and Eli Lilly have entered a partnership to use Insilico’s AI‑driven Pharma.AI platform for discovering new oral therapeutics across several disease areas. Lilly receives an exclusive worldwide license to develop, manufacture and commercialize the preclinical candidates, while Insilico secures...
New Data Show TrenibotE Safety in Repeat Treatments
Allergan Aesthetics presented new Phase 3 data on its investigational neurotoxin TrenibotE at the 2026 American Academy of Dermatology meeting. The open‑label study evaluated up to three repeat glabellar line treatments, confirming a consistent safety profile, no neutralizing antibodies, rapid onset...
Elidah Reports US FDA Clearance of Elitone for Men to Treat Post-Prostatectomy Urinary Incontinence
Elidah announced that the U.S. Food and Drug Administration has cleared its at‑home device, Elitone for Men, to treat urinary incontinence after prostate surgery. The non‑invasive system delivers neuromuscular stimulation to the pelvic floor for a 20‑minute daily session, eliminating...
The Brave New World of Radiotherapeutics
Radiotherapeutics have moved from niche concepts to a burgeoning oncology platform, driven by unmet treatment gaps and the commercial breakthrough of Novartis' Pluvicto. Early data show Actinium‑225 delivering 45‑50% response rates in heavily pre‑treated prostate cancer, while Bayer's Xofigo adds...
AskBio Announces Completion of Enrollment in Phase 2 Clinical Trial of AB-1002 Investigational Gene Therapy for Heart Failure
AskBio, a Bayer subsidiary, announced that enrollment for its GenePHIT Phase 2 trial of the investigational gene therapy AB‑1002 has been completed, randomizing 173 patients with non‑ischemic cardiomyopathy and NYHA Class III heart‑failure symptoms. The trial, spanning 46 sites across North America...
The Deep-Tech Founder Using AI to Address Immunology Challenges
Camille Bouget, CEO and co‑founder of Scienta Lab, launched EVA, a multimodal AI platform designed to accelerate immunology drug development. The model helps R&D teams identify viable therapeutic targets, predict preclinical efficacy, and stratify patients for clinical trials. By applying...
The Role of Ethical Oversight and Algorithmic Bias in Automated Pharmacovigilance
Pharmacovigilance is rapidly adopting machine learning, natural language processing, and automation to ingest, categorize, and prioritize adverse event reports, dramatically shrinking backlogs and accelerating signal detection. While these technologies deliver speed and scale, they also inherit reporting biases and can...
Antipsychotic-Like Effects of the Selective Rho-Kinase 2 Inhibitor KD025 in Genetic and Pharmacological Mouse Models of Schizophrenia
The selective ROCK2 inhibitor KD025 (belumosudil) demonstrated antipsychotic‑like activity in both genetic (Arhgap10 S490P/NHEJ) and pharmacological (methamphetamine and MK‑801) mouse models of schizophrenia. KD025 restored reduced spine density in the medial prefrontal cortex and rescued deficits in a touchscreen visual‑discrimination...
Jupiter Neurosciences Inc (JUNS) Q4 2025 Earnings Call Transcript
Jupiter Neurosciences reported total product sales of $2.8 billion in 2025, a 22% year‑over‑year increase driven by INGREZZA and the debut of CRENESSITY. INGREZZA generated just over $2.5 billion, up 9% on volume growth, while CRENESSITY posted $300 million in its first full...
Weight-Loss Jabs Will Be Offered on NHS for People at Risk of Further Heart Attacks
The National Institute for Health and Care Excellence (NICE) has approved the GLP‑1 drug Wegovy (semaglutide) for free on the NHS to more than one million English patients who are overweight and have a history of heart attacks, strokes or...
From Free Rider to Innovator: How China Became a Global Pharmaceutical Powerhouse
China has transformed from a pharmaceutical free rider into a leading innovator, largely after the 2016 National Reimbursement Drug List (NRDL) reform. The policy slashed prices by 50‑60% while guaranteeing near‑universal coverage, prompting a five‑fold rise in annual clinical trials...
How Ireland Became Dependent on Big Pharma — and the Risks Ahead
Over the past five decades Ireland has transformed into the world’s third‑largest pharmaceutical exporter, with drug manufacturing now contributing roughly 20 % of its GDP. The sector’s rapid growth was driven by generous tax incentives, a skilled workforce and proximity to...
Dual-Target Strategy Shows Promise in Overcoming Drug Resistance in MCL
A recent preclinical study identified BIRC5 and MCL‑1 as co‑drivers of survival in mantle cell lymphoma (MCL) and demonstrated that simultaneous inhibition with YM155 and S63845 produces strong synergistic killing of cancer cells. The combination was effective across both treatment‑naïve...
Targeting Tumor Supporting Cells: Lipid Nanoparticles Advance CAR T Success in Pancreatic Cancer
Researchers at Penn Vet used lipid nanoparticles (LNPs) to deliver FAP‑CAR mRNA directly to patients' T cells, enabling in‑vivo engineering of CAR T cells that attack cancer‑associated fibroblasts in pancreatic ductal adenocarcinoma. In a preclinical mouse model, a single dose of...
Off-the-Shelf CAR T-Cell Therapy Granted Breakthrough Therapy Designation for Aggressive T-Cell Cancers
Soficabtagene geleucel (WU‑CART‑007), an off‑the‑shelf CRISPR‑engineered CAR‑T therapy, received FDA Breakthrough Therapy Designation for relapsed or refractory T‑cell leukemia and lymphoma. In a phase 1/2 trial of 28 patients, the drug achieved a 91% overall response rate and a 73% complete...
Using “Left-Handed” Proteins to Block Alzheimer’s
Kobe University researchers engineered a synthetic right‑handed (D) peptide that binds amyloid‑beta, the disordered protein driving Alzheimer’s plaques, and blocks its aggregation. In mouse brain cell cultures the mirror peptide restored cell viability to 100%, compared with 50% survival when...
Key Takeaways: AI-Assisted Innovation and Patent Protection in Biotech
AI‑assisted tools are reshaping biotech research, delivering faster discovery and more complex experiments. A recent Sterne Kessler webinar clarified that U.S. patent law still requires a human to be named as inventor, even when AI contributes substantially. Inventorship is judged claim‑by‑claim,...
4th Circuit Upholds Block on West Virginia’s 340B Law
The Fourth Circuit affirmed a preliminary injunction that blocks West Virginia’s Senate Bill 325, which would have forced drug manufacturers to extend 340B discounts to prescriptions filled by contract pharmacies. The injunction, originally issued by a West Virginia district court,...
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Nanobiotix posted full‑year 2025 results showing a revenue rebound to roughly $35.5 million and a net loss of $26 million, a 65% YoY improvement. The company secured a non‑dilutive royalty financing of up to $71 million, extending its cash runway to early 2028 with...
Frailty, Innovation, and the Future of Myeloma Treatment With Joseph Mikhael, MD
Joseph Mikhael, MD, highlights a dramatic shift in multiple myeloma care for older adults, driven by refined frailty assessments and the rise of targeted immunotherapies such as CAR‑T cells and bispecific antibodies. These advances have translated into higher survival rates...
Key Neurons Can Jumpstart Leg Movement After Spinal Injury
Researchers identified a rare subset of graft‑derived interneurons that can reconnect broken spinal circuits and trigger leg muscle activity in animal models of spinal cord injury. When these neurons were experimentally activated, 20‑30% of the subjects showed measurable leg movements,...
Pharma Goes on $25.5B, Eight-Day Acquisition Spree
Pharmaceutical companies launched an eight‑day acquisition blitz, with six firms announcing deals worth about $25.5 billion. Two of those transactions involve upfront payments exceeding $5 billion each, underscoring the aggressive pace. The deals focus on securing biotech pipelines and specialty drug assets...
TippingPoint Raises $4.5M Seed to Drug Hidden Epigenetic Targets in Deadly Pediatric Brain Cancer
TippingPoint Biosciences announced a $4.5 million seed round led by SOSV and LKS Fund to advance its epigenetic drug discovery platform. The company targets protein‑protein interfaces within disease‑specific chromatin environments, aiming at sites traditionally deemed undruggable. Its inaugural program focuses on...
Yuvezzi for Presbyopia Now Available in US
Tenpoint Therapeutics announced that Yuvezzi, the first FDA‑approved eye‑drop for presbyopia, is now commercially available in the United States. The formulation combines carbachol 2.75 % and brimonidine tartrate 0.1 % to induce pupil constriction within 30 minutes, providing up to ten hours...
Vanda’s Tradipitant Has Phase II Success but a Court Setback
Vanda Pharmaceuticals reported that its NK1‑receptor antagonist tradipitant achieved its primary endpoint in a Phase II trial for gastroparesis, showing a roughly 30% improvement in nausea scores versus placebo. The data suggest the drug could address a sizable unmet need in...
AI-Built Intrabodies Target Alzheimer’s Within
University of Essex researchers used artificial intelligence to redesign antibody fragments, creating "intrabodies" that remain stable inside human cells. By adjusting electrical charge, they converted 672 antibodies into intracellularly functional molecules that bind disease‑causing proteins linked to Alzheimer’s, Parkinson’s, Huntington’s...
Novo Nordisk Cuts Starting Price of Ozempic by 36% and Wegovy by 48%
Novo Nordisk announced that, effective April 1 2026, the starting dose of its GLP‑1 drugs Ozempic and Wegovy will be reduced by 36% and 48% respectively in India. The new price for the 0.25 mg dose is ₹202 per day (about $2.44) or...
Scientists Have Discovered an 'Achilles' Heel' In Deadly Superbugs
Scientists have identified pseudaminic acid, a sugar found only on the surface of certain Gram‑negative bacteria, as a vulnerable target. By synthesizing this sugar and creating monoclonal antibodies that bind it, researchers demonstrated in mice that the antibodies flag the...
Modified Immune Cells Target Cancer’s Metabolic Signature
Stanford researchers engineered natural killer (NK) and cytotoxic T cells to overexpress metabolite‑sensing G protein‑coupled receptors, most notably GPR183, enabling the cells to home toward tumor‑derived metabolic cues. In mouse models of triple‑negative breast and ovarian cancer, GPR183‑enhanced NK‑92 cells...
Polysaccharide Microneedles and 3D Printing Explored for Cancer Immunotherapy Applications
Researchers reviewed polysaccharide‑based microneedles as a platform for cancer immunotherapy, emphasizing how additive manufacturing—particularly high‑resolution 3D printing—can create customizable transdermal delivery arrays. Natural polymers such as hyaluronic acid, chitosan and alginate provide biocompatibility and enable dissolvable or hydrogel‑based needles with...
DiaMedica Therapeutics Inc. (DMAC) Q4 2025 Earnings Call Transcript
DiaMedica Therapeutics reported Q4 2025 revenue of $45 million, a 30% year‑over‑year increase, and ended the quarter with $200 million in cash, extending its runway to 2028. The company announced that the FDA granted Fast Track designation for its DM‑101 oncology candidate, and...
Biogen, with $5.6B Apellis Buy, Builds Out Immunology Offerings
Biogen announced a $5.6 billion cash acquisition of Apellis Pharmaceuticals, paying $41 per share—a 140% premium—and issuing contingent value rights worth up to $4 per share. The deal brings two recently launched products, the eye‑disease therapy Syfovre and the rare‑kidney drug...
Short-Acting Psychedelic DMT Shows Promise as a Rapid Treatment for Major Depressive Disorder
A phase IIa trial published in Nature Medicine found that a single intravenous dose of dimethyltryptamine (DMT), paired with structured psychotherapy, produced a rapid and sustained reduction in major depressive disorder symptoms. Participants receiving 21.5 mg of DMT showed an average...
Henan Lvyuan Pharmaceutical Co. Ltd. - 722497 - 03/26/2026
The FDA issued a warning letter to Henan Lvyuan Pharmaceutical after a September 2025 inspection uncovered multiple Current Good Manufacturing Practice (CGMP) violations. Inspectors cited severe facility maintenance issues, including corrosion and water leaks that could compromise API potency and...
Microbiological Testing & Consulting, LLC - 720374 - 03/16/2026
The FDA issued Warning Letter 320‑26‑53 to Microbiological Testing & Consulting, LLC after a September 2025 inspection uncovered multiple Current Good Manufacturing Practice (CGMP) violations. The firm failed to maintain adequate laboratory controls, documentation, media qualification, and a functional quality‑control unit,...
FDA Identifies Cases of Serious Liver Injury in Patients Taking Tavneos (Avacopan) for Severe Active Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-Associated Vasculitis
The FDA issued a drug safety communication warning that Tavneos (avacopan) is linked to 76 post‑marketing cases of drug‑induced liver injury, including eight fatalities. Seven patients developed biopsy‑confirmed vanishing bile duct syndrome, a severe cholestatic condition, with three deaths. Median...
Coronavirus Aid, Relief, and Economic Security Act (CARES Act) Drug Shortage Mitigation Efforts
The CARES Act, enacted in March 2020, added new authorities to the FDA to curb drug shortages by requiring manufacturers to notify the agency of permanent discontinuances and production interruptions. It also mandates the creation of site‑specific risk‑management plans and...
Companies that Have Not Submitted Drug Amount Reports
The FDA has released two public lists identifying registrants that failed to submit required drug amount reports for calendar year 2024. One list covers entities with active drug listings, the other captures those with inactive listings. Registrants must certify or...
October - December 2025 | New Safety Information or Potential Signals of Serious Risks Identified by the FDA Adverse Event...
The FDA’s Adverse Event Monitoring System (AEMS) released a slate of new safety signals for a range of products covering October‑December 2025. Alerts include heightened hypersensitivity reactions for certain lots of Alyglo, hypogammaglobulinemia linked to multiple bispecific T‑cell engager therapies,...
Longer-Term Real-World Data Needed to Compare Leqembi and Kisunla Opposing Treatment Strategies for Alzheimer’s
Eisai/Biogen’s Leqembi and Eli Lilly’s Kisunla are the only FDA‑approved disease‑modifying Alzheimer’s therapies, but they follow opposite treatment models—continuous dosing versus a finite course after amyloid clearance. Four‑year data presented at AD/PD 2026 showed Leqembi delayed disease progression by roughly 9.8 months, with...